Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

Affiliations

• ¹ Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University, Ulm, Germany.
• ² Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
• ³ Università Vita-Salute San Raffaele and Ospedale San Raffaele, Milan, Italy.
• ⁴ Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.
• ⁵ German Cancer Research Center, Heidelberg, Germany.
• ⁶ Translational Medicine, Hematology Research and Development, AstraZeneca, South San Francisco, CA.
• ⁷ Research and Development, Maverick Therapeutics, Brisbane, CA.
• ⁸ Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; and.
• ⁹ Clinical Genetics, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.